{
    "clinical_study": {
        "@rank": "40307", 
        "acronym": "PARIDA", 
        "arm_group": [
            {
                "arm_group_label": "paracetamol", 
                "arm_group_type": "Experimental", 
                "description": "Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days."
            }, 
            {
                "arm_group_label": "Intravenous ibuprofen", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days."
            }
        ], 
        "brief_summary": {
            "textblock": "Current pharmacological options to treat an hemodynamically significant PDA (HsPDA) in\n      preterm infants are limited to non-selective cyclo-oxygenase (COX) inhibitors, indomethacin\n      or ibuprofen. Recently paracetamol exposure has been reported to successful closure of PDA.\n      Aim of this randomized double-blind controlled study is to compare the efficacy and the\n      safety of standard PDA treatment ibuprofen  versus paracetamol-experimental treatment . We\n      hypothesize that paracetamol is more effective than ibuprofen in closing PDA, perhaps\n      ameliorating the safety profile of the pharmacological treatment."
        }, 
        "brief_title": "Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ductus Arteriosus Patent", 
            "Respiratory Distress Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ductus Arteriosus, Patent", 
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objective of this trial is to compare the efficacy and safety of 2 therapeutic regimens\n      for PDA treatment in a population of preterm newborns of gestational age (GA) <31+6 weeks\n      with respiratory distress syndrome (RDS) and HsPDA:\n\n        -  Group A: experimental boluses of paracetamol at 15 mg/Kg four time a day for three\n           consecutive days.\n\n        -  Group B: standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three\n           consecutive days.\n\n      The primary objective of the study is: to evaluate the efficacy of paracetamol versus\n      standard ibuprofen regimen, by comparing the rate of ductal closure after the first and\n      second course of pharmacological treatment. (PDA diagnosed by ECHO criteria)\n\n      The secondary objective of the study is: to evaluate the safety of the above 2 therapeutic\n      regimens in term of incidence of transient renal impairment, intraventricular hemorrhage\n      (IVH) or other bleeding disorders, necrotizing enterocolitis (NEC) and isolated bowel\n      perforation (without signs of NEC), incidence of sign of liver toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  inborn neonates\n\n          -  preterm neonates \u2264 31+ 6 days weeks gestation\n\n          -  newborns with HsPDA\n\n          -  parental written informed consent for participation in the study must be obtained\n\n        Exclusion Criteria:\n\n          -  Serum creatinine concentration greater than 1,5 mg/dl (132MMole/L)\n\n          -  Urine output less than 1 ml/Kg/h\n\n          -  Severe IVH (> grade II according to Volpe classification)\n\n          -  Clinical bleeding tendency (as revealed by hematuria, blood in the gastric aspirate\n             or in the stools, blood in the endotracheal tube aspirate)\n\n          -  Necrotizing enterocolitis or marked abdominal distention with gastric bile residuals\n\n          -  Thrombocyte count of less than 50.000/mm3\n\n          -  Proved Sepsis\n\n          -  Severe coagulopathy or liver failure\n\n          -  Evidence of severe birth asphyxia, that is an APGAR score below 5 at 5 minutes of age\n             and/or umbilical arterial pH < 7.0\n\n          -  Known genetic or chromosomal disorders\n\n          -  Participation in another clinical trial of any placebo, drug, biological, or device\n             conducted under the provisions of a protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "72 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056223", 
            "org_study_id": "PARIDA 01/2013", 
            "secondary_id": "2013-004955-19"
        }, 
        "intervention": [
            {
                "arm_group_label": "paracetamol", 
                "description": "15 mg/Kg every 6 hours for three days", 
                "intervention_name": "Intravenous paracetamol", 
                "intervention_type": "Drug", 
                "other_name": "Perfalgan i.v."
            }, 
            {
                "arm_group_label": "Intravenous ibuprofen", 
                "description": "10 -5-5 mg/Kg once a day for three days", 
                "intervention_name": "Intravenous ibuprofen", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Pedea i.v.", 
                    "NeoProfen i.v."
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Ibuprofen"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Patent ductus arteriosus", 
            "Preterm infant", 
            "Paracetamol", 
            "Ibuprofen"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "lago@pediatria.unipd.it", 
                "last_name": "Paola Lago, MD", 
                "phone": "0039 049 821", 
                "phone_ext": "3545"
            }, 
            "contact_backup": {
                "email": "salvadori@pediatria.unipd.it", 
                "last_name": "Sabrina Salvadori, MD", 
                "phone": "0039 049 821", 
                "phone_ext": "3546"
            }, 
            "facility": {
                "address": {
                    "city": "Padua", 
                    "country": "Italy", 
                    "zip": "35128"
                }, 
                "name": "NICU, Women's and Children's Health Department, Azienda Ospedaliera-University of Padua"
            }, 
            "investigator": [
                {
                    "last_name": "Paola Lago, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sabrina Salvadori, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lino Chiandetti, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anna Chiara Frigo, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Roberto Padrini, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial.", 
        "other_outcome": [
            {
                "description": "Rate of NEC in the paracetamol and ibuprofen group", 
                "measure": "Necrotizing enterocolitis (NEC)", 
                "safety_issue": "Yes", 
                "time_frame": "In the first 14 days of life"
            }, 
            {
                "description": "Rate of intraventricular haemorrhage (IVH) or death within 28 days of life (composite outcome).", 
                "measure": "Intraventricular haemorrhage (IVH) or death", 
                "safety_issue": "Yes", 
                "time_frame": "Within 28 days of life"
            }
        ], 
        "overall_contact": {
            "email": "lago@pediatria.unipd.it", 
            "last_name": "Paola Lago, MD", 
            "phone": "0039 049 821", 
            "phone_ext": "3545"
        }, 
        "overall_contact_backup": {
            "email": "salvadori@pediatria.unipd.it", 
            "last_name": "Sabrina Salvadori, MD", 
            "phone": "0039 049 821", 
            "phone_ext": "3546"
        }, 
        "overall_official": {
            "affiliation": "Women's and Children's Health Department- AO- University of Padua", 
            "last_name": "Paola Lago, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The rate of ductal closure after the first and second course of pharmacological treatment. (PDA diagnosed by ECHO criteria) in paracetamol versus ibuprofen group", 
            "measure": "PDA pharmacological closure", 
            "safety_issue": "No", 
            "time_frame": "Partecipants will be evaluated at the end of first and second course, at an expected avarage of 8 days of life (DOL)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056223"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Padua", 
            "investigator_full_name": "Paola Lago", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "23258386", 
                "citation": "Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, Dilmen U. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013;103(3):166-9. doi: 10.1159/000345337. Epub 2012 Dec 19."
            }, 
            {
                "PMID": "22065264", 
                "citation": "Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011 Dec;128(6):e1618-21. doi: 10.1542/peds.2011-0359. Epub 2011 Nov 7."
            }, 
            {
                "PMID": "22611117", 
                "citation": "Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, Erdeve O, Dilmen U. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013 Jan;98(1):F94. doi: 10.1136/archdischild-2012-302044. Epub 2012 May 18."
            }, 
            {
                "PMID": "21317433", 
                "citation": "Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child. 2011 Jun;96(6):575-80. doi: 10.1136/adc.2010.204552. Epub 2011 Feb 13."
            }
        ], 
        "secondary_outcome": {
            "description": "Rate of oliguria defined as a reduction on urine output less than 1ml/Kg/h,", 
            "measure": "Oliguria", 
            "safety_issue": "Yes", 
            "time_frame": "In the first 14 days of life"
        }, 
        "source": "University of Padua", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Padua", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}